The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system
Authors
Keywords
SMYD, Methyltransferases, Epigenetics, Immunology, Cancer, Muscle
Journal
Heliyon
Volume 7, Issue 6, Pages e07387
Publisher
Elsevier BV
Online
2021-06-24
DOI
10.1016/j.heliyon.2021.e07387
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias
- (2020) Mark A. Brown et al. GENES AND IMMUNITY
- SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
- (2020) Cinzia Bottino et al. Cancers
- Leishmania donovani Subverts Host Immune Response by Epigenetic Reprogramming of Macrophage M(Lipopolysaccharides + IFN-γ)/M(IL-10) Polarization
- (2020) Naveen Parmar et al. JOURNAL OF IMMUNOLOGY
- The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells
- (2020) Machiko Kojima et al. Oncology Letters
- A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets
- (2019) Juan Bayo et al. JOURNAL OF HEPATOLOGY
- Clinical presentation and genetic profiles of Chinese patients with velocardiofacial syndrome in a large referral centre
- (2019) Dandan Wu et al. JOURNAL OF GENETICS
- STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo
- (2019) Fujia Lin et al. INFLAMMATION RESEARCH
- Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity
- (2019) Jodie Hay et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Histone methyltransferase SMYD2: ubiquitous regulator of disease
- (2019) Xin Yi et al. Clinical Epigenetics
- Overexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with poor prognosis in pediatric B lineage acute lymphoblastic leukemia
- (2019) Ping Zhang et al. LEUKEMIA & LYMPHOMA
- SMYD1 is the underlying gene for the AnWj negative blood group phenotype
- (2018) Vered Yahalom et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Tumor necrosis factor-alpha inhibitors suppress CCL2 chemokine in monocytes via epigenetic modification
- (2017) Yi-Ching Lin et al. MOLECULAR IMMUNOLOGY
- Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck
- (2017) Theodore Vougiouklakis et al. Oncotarget
- SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress
- (2017) Adi Zipin-Roitman et al. Oncotarget
- GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1
- (2016) M. Velinder et al. BIOCHEMICAL JOURNAL
- Berberine acts as a putative epigenetic modulator by affecting the histone code
- (2016) Zhixiang Wang et al. TOXICOLOGY IN VITRO
- Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia
- (2016) Wilson Oliveira-Santos et al. TUMOR BIOLOGY
- Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis
- (2016) Sevgi Bagislar et al. Oncotarget
- Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations
- (2015) Jan Peveling-Oberhag et al. BMC CANCER
- Structure and Function of SET and MYND Domain-Containing Proteins
- (2015) Nicholas Spellmon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Histone Methyltransferase Smyd2 Is a Negative Regulator of Macrophage Activation by Suppressing Interleukin 6 (IL-6) and Tumor Necrosis Factor α (TNF-α) Production
- (2015) Guiliang Xu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
- (2015) Hannah Nguyen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection
- (2015) D E de Almeida Nagata et al. Mucosal Immunology
- SMYD Proteins: Key Regulators in Skeletal and Cardiac Muscle Development and Function
- (2014) Shao Jun Du et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor
- (2014) Luis Henrique Toshihiro Sakamoto et al. LEUKEMIA RESEARCH
- Control of Proinflammatory Gene Programs by Regulated Trimethylation and Demethylation of Histone H4K20
- (2012) Joshua D. Stender et al. MOLECULAR CELL
- Transcriptional Regulation of 15-Lipoxygenase Expression by Histone H3 Lysine 4 Methylation/Demethylation
- (2012) Cheng Liu et al. PLoS One
- SMYD3 interacts with HTLV-1 Tax and regulates subcellular localization of Tax
- (2010) Keiyu Yamamoto et al. CANCER SCIENCE
- Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells
- (2010) Fei Zhao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF
- (2009) Jia-Ning Zou et al. CANCER LETTERS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started